远程医疗平台Hims & Hers Health（HIMS）股价今日盘中大涨5.14%，引发市场关注。这一涨势可能与公司最近在减肥药物分销争议中的强硬立场有关。
近日，丹麦制药巨头诺和诺德（Novo Nordisk）终止了与Hims & Hers Health分销减肥疗法Wegovy的合作关系。诺和诺德指控Hims & Hers违反相关法律，以"个性化"为幌子大规模销售Wegovy的复方药物。然而，Hims & Hers首席执行官Andrew Dudum表示，公司将继续通过其远程医疗平台提供廉价的Wegovy复方药物。
Dudum强调，尽管面临压力，公司仍将坚持为客户利益而战。他表示："我们拒绝被任何制药公司的反竞争要求所胁迫，这些要求侵犯了供应商的独立决策，限制了患者的选择。"这一坚定立场似乎得到了投资者的认可，推动了股价的上涨。此前，在诺和诺德宣布终止合作后，Hims & Hers的股价曾出现大幅下跌。今日的反弹可能表明市场对公司战略的信心正在恢复。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.